Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to redefine oral incretin therapy

New analyses of the ATTAIN program highlight Foundayo's profile in patient populations central to the future of cardiometabolic care, including women at every stage of menopause

Pivotal Phase 3 results showed retatrutide, a first-in-class triple receptor agonist, delivered powerful results in obesity, type 2 diabetes and other complications

INDIANAPOLIS, May 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide), Foundayo (orforglipron) and retatrutide, will present new data across its cardiometabolic portfolio at the American Diabetes Association's 86th Scientific Sessions taking place June 5-8 in New Orleans. Together, these findings position Lilly to lead the next era of cardiometabolic care, with a differentiated suite of approved and investigational medicines built to expand choice for the millions living with obesity, diabetes and related conditions.